Loading...
BIO
XNYS
Market cap9.65bUSD
Nov 20, Last price  
358.90USD
1D
-2.34%
1Q
-5.56%
Jan 2017
96.89%
Name

Bio Rad Laboratories Inc

Chart & performance

D1W1MN
XNYS:BIO chart
P/E
12.70
P/S
3.74
EPS
28.26
Vol. 1Y
36.24%
Shs. 5Y
-1.99%
Rev. 5Y
0.29%
Div Yld LY
—
Div Yld TTM
—
Revenues
2.58b
+0.65%
1,273,930,0001,461,052,0001,764,365,0001,784,244,0001,927,118,0002,073,529,0002,069,235,0002,132,694,0002,175,044,0002,019,441,0002,068,172,0002,160,153,0002,290,109,0002,311,659,0002,545,626,0002,922,545,0002,802,249,0002,671,262,0002,566,500,0002,583,200,000
Net income
760m
P
103,263,00092,994,00089,510,000144,620,000185,490,000178,223,000169,234,00077,790,00088,845,000113,093,00028,125,000114,740,000360,996,0001,758,675,0003,814,229,0004,254,257,000-3,627,535,000-637,324,000-1,844,200,000759,900,000
CFO
532m
+16.92%
118,229,000191,580,000191,371,000325,074,000225,909,000262,735,000266,480,000169,136,000273,312,000186,210,000216,066,000104,137,000285,494,000457,897,000584,972,000669,464,000194,447,000374,943,000455,200,000532,200,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

Related entities

Subsidiaries (2)
BIO RAD LABORATORIES MANUFACTURE AND TRADE OF MEDICAL EQUIPMENT SINGLE MEMBER LIMITED LIABILITY COPANY
Bio - Rad Laboratories Gesellschaft mit beschränkter Haftung

Key people

Norman Schwartz
Chairman of the Board, Chief Executive Officer · since 2024
President, Chief Operating Officer · since 2024
Roop Lakkaraju
Chief Financial Officer, Executive Vice President · since 2024
James Barry
Executive Vice President, President - Life Science Group · since 2024
Michael Crowley
Executive Vice President - Global Commercial Operations · since 2014
Eva Anette Engelhardt
Executive Vice President, President of Clinical Diagnostics Group · since 2024
Courtney Enloe
Executive Vice President, General Counsel, Secretary · since 2024
Sedat Evran
Executive Vice President - Global Supply Chain · since 2023
Rajat Mehta
Executive Vice President - Global Commercial Operations · since 2025
Colleen Corey
Executive Vice President, Global Human Resources · since 2019
Allison Schwartz
Director · since 2022
Independent Director · since 2017
Lead Independent Director · since 2017
Independent Director · since 2017
Arnold Pinkston
Independent Director · since 2017
IPO date
Mar 17, 1980
Employees
8,200
Domiciled in
US
Incorporated in
US
Legal address
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
1000 Alfred Nobel Drive,
Hercules, CA 94547
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT